文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-NOTA-FAPI-04 PET/CT代谢参数联合血液生物标志物预测食管鳞状细胞癌新辅助放化疗后病理完全缓解

18F-NOTA-FAPI-04 PET/CT metabolic parameters combined with hematological biomarkers predict pathological complete response after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-09-15

回顾性纳入2022年3月至2023年5月在山东省肿瘤医院接受新辅助放化疗后手术的19例局部晚期食管鳞状细胞癌患者,分析治疗前18F-NOTA-FAPI-04 PET/CT代谢参数与血液生物标志物对病理完全缓解的预测价值。多因素分析显示MTV(OR=0.978,p=0.017)和血小板计数(OR=1.003,p=0.016)为独立预测因子,两参数联合模型AUC为0.909。

要点

  • 19例中11例达pCR、8例非pCR,MTV与PLT为pCR独立预测因子。
  • 联合模型AUC 0.909,优于单独MTV(0.716)或PLT(0.761)。
  • 列线图显示较低MTV(最佳阈值≤27.47)与较高PLT(最佳阈值≥330.5)与更高pCR可能性相关。

核心结论

  • 治疗前18F-NOTA-FAPI-04 PET/CT衍生的MTV联合血小板计数可无创预测食管鳞状细胞癌患者新辅助放化疗后的pCR,为个体化治疗策略提供依据。

研究设计与样本

  • 回顾性研究纳入2022年3月至2023年5月在山东省肿瘤医院接受新辅助放化疗后手术的19例局部晚期食管鳞状细胞癌患者。
  • 收集治疗前临床基线数据、18F-NOTA-FAPI-04 PET/CT代谢参数和血液生物标志物,采用单因素和多因素logistic回归筛选预测参数。
  • 构建预测pCR的logistic回归模型,并用受试者工作特征曲线、决策曲线和列线图评价其性能。

主要发现

  • 19例患者中11例达pCR、8例为非pCR。
  • 多因素分析确定MTV(OR=0.978,p=0.017)和血小板计数(OR=1.003,p=0.016)为pCR的独立预测因子。
  • 两参数联合模型AUC为0.909,显著优于单指标(MTV AUC=0.716;PLT AUC=0.761)。
  • 列线图显示较低MTV(最佳阈值≤27.47)和较高PLT(最佳阈值≥330.5)与更高的pCR可能性相关。

关键数值与推荐

  • MTV的OR=0.978(p=0.017),血小板计数的OR=1.003(p=0.016),均为pCR的独立预测因子。
  • 联合模型AUC=0.909,MTV单独AUC=0.716,PLT单独AUC=0.761。
  • MTV最佳阈值≤27.47,PLT最佳阈值≥330.5。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the predictive value of pretreatment 18F-NOTA-FAPI-04 PET/CT metabolic parameters combined with hematological biomarkers for pathological complete response (pCR) after neoadjuvant chemoradiotherapy (nCRT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC). METHODS: This retrospective study included 19 patients with locally advanced ESCC who underwent nCRT followed by surgery at Shandong Cancer Hospital from March 2022 to May 2023. Pretreatment clinical baseline data, 18F-NOTA-FAPI-04 PET/CT metabolic parameters, and hematological biomarkers were collected. Univariate and multivariate logistic regression analyses were used to select predictive parameters. A logistic regression model was constructed to predict pCR, and its performance was evaluated using receiver operating characteristic (ROC) curves, decision curves, and a nomogram. RESULTS: Among 19 patients, 11 achieved pCR, and 8 achieved non-pCR status. Univariate and multivariate analyses identified metabolic tumor volume (MTV) (OR = 0.978, p = 0.017) and platelet count (PLT) (OR = 1.003, p = 0.016) as independent predictors of pCR. By fitting a logistic regression model, the two-parameter joint model reached an AUC of 0.909, which was significantly better than the single indicator (MTV, AUC = 0.716; PLT, AUC = 0.761). The nomogram demonstrated that lower MTV (optimal threshold ≤ 27.47) and higher PLT (optimal threshold ≥ 330.5) values were associated with a higher likelihood of pCR. CONCLUSION: Pretreatment 18F-NOTA-FAPI-04 PET/CT-derived MTV combined with PLT can noninvasively predict pCR after nCRT in ESCC patients, providing a basis for personalized treatment strategies.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Cui Y, Wang H, Wang N, et al. 18F-NOTA-FAPI-04 PET/CT metabolic parameters combined with hematological biomarkers predict pathological complete response after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2025. PMID: 40952470. doi:10.1007/s00259-025-07506-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。